Dyax Corp., a prominent biopharmaceutical company headquartered in the United States, has been at the forefront of developing innovative therapies since its founding in 1995. Specialising in the field of rare diseases, particularly in the treatment of hereditary angioedema, Dyax has made significant strides in advancing patient care through its unique product offerings.
The company is renowned for its flagship product, Kalbitor, which provides rapid relief for acute attacks of hereditary angioedema. Dyax's commitment to research and development has positioned it as a leader in the biopharmaceutical industry, with a strong focus on utilising its proprietary technology platforms to discover and develop novel therapeutics. With a robust pipeline and a dedication to improving patient outcomes, Dyax Corp. continues to solidify its reputation as a key player in the biopharmaceutical landscape.
+38 vs industry average
Dyax Corp.’s score of 76 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Dyax Corp.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Dyax Corp. yet.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Dyax Corp.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Dyax Corp. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Takeda Pharmaceutical Company Limited
Carbon Disclosure Project
Inherited from Takeda Pharmaceutical Company Limited
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Takeda Pharmaceutical Company Limited
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Dyax Corp.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project